CDKN2A, cyclin dependent kinase inhibitor 2A, 1029

N. diseases: 1314; N. variants: 146
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 Biomarker disease BEFREE In the present study, the efficacy of mouse p16 peptide administration in a mouse lung metastasis model for BT and also the toxicity of peptides by cardiac peptide injection were evaluated. 30655885 2019
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 Biomarker disease BEFREE Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973). 30446453 2019
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 GeneticVariation disease BEFREE Significantly higher rates of TP53 and CDKN2A mutation rates (p = 0.005 and 0.035, respectively) were encountered in muscle-invasive bladder tumors compared with those of pT1 stage. 31028363 2019
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 GeneticVariation disease BEFREE Mutations in CDKN2A and the FGFR3 genes on bladder cancer diagnosis: a systematic review and meta-analysis. 31028457 2019
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 AlteredExpression disease BEFREE Curcumin Suppresses microRNA-7641-Mediated Regulation of p16 Expression in Bladder Cancer. 30149755 2018
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 Biomarker disease BEFREE However, P16 gene amplification accompanied protein high-expression has shorter overall survival compared with the overall patients (P = .023), and P16 gene loss accompanied loss of protein also had the tendency to predict bad prognosis (P = .067).Studies show that the genetic status of P16 has a close relation with the stages of bladder cancer. 29642177 2018
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 Biomarker disease BEFREE Collectively, we provided evidence that Jarid2 via modulation of p16 is a putative novel therapeutic target for treating malignant bladder cancer. 28445934 2017
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 Biomarker disease BEFREE We identified a miR-877-3p binding site on the promoter site of tumor suppressor gene p16 which alters frequently in bladder cancer. 27429046 2016
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 Biomarker disease BEFREE In conclusion, DE-miRNAs in bladder cancer tissue samples and DE-targeted genes, such as miR-106b and CDKN2A, which were identified in the present study, may provide the basis for targeted therapy for breast cancer and enhance understanding of its pathogenesis. 25955758 2015
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 AlteredExpression disease BEFREE Detection of human papillomavirus infection and p16 immunohistochemistry expression in bladder cancer with squamous differentiation. 24675970 2014
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 GeneticVariation disease BEFREE ASSET analyses identified four SNPs significantly associated with multiple cancers: rs3731239 (CDKN2A intronic) with ESCC, GC and BC (P = 3.96 × 10(-) (4)); rs10811474 (3' of IFNW1) with RCC and BrC (P = 0.001); rs12683422 (LINGO2 intronic) with RCC and BC (P = 5.93 × 10(-) (4)) and rs10511729 (3' of ELAVL2) with LC and BrC (P = 8.63 × 10(-) (4)). 25239644 2014
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 Biomarker disease BEFREE Thus, the systemic peptide delivery of p16 restores the hypophosphorylation of pRb and may be a useful tool for the treatment of bladder tumors. 23292502 2013
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 PosttranslationalModification disease BEFREE p14 hypermethylation could be involved in early stage of bladder carcinogenesis, and p14 hypermethylation in pathologically normal urothelium samples should be considered a predictor of bladder cancer recurrence. 20800513 2012
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 PosttranslationalModification disease BEFREE Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer. 23083854 2012
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 PosttranslationalModification disease BEFREE We analyzed the methylation of P16INK4a and P14ARF in 80 tissues and matched blood samples of patients suffering from bladder cancer and 80 blood samples of cancer-free individuals by MS-PCR. 20683150 2010
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 Biomarker disease LHGDN Large-scale analysis of cell cycle regulators in urothelial bladder cancer identifies p16 and p27 as potentially useful prognostic markers. 18334837 2008
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 Biomarker disease BEFREE Here we show that low-level expression of a constitutively active Ha-ras in mouse urothelium induces simple urothelial hyperplasia that is resistant to progression to full-fledged bladder tumors even in the absence of Ink4a/Arf. 17256055 2007
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 AlteredExpression disease BEFREE To evaluate the prognostic role of p16 expression and loss of heterozygosity (LOH) on chromosome 9p21 in patients affected by low-grade (G1-G2) urothelial bladder cancer. 17612565 2007
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 Biomarker disease BEFREE We, therefore, examined, in a population-based study of human bladder cancer, the relationship between epigenetic silencing of three tumor suppressor genes, p16(INK4A), RASSF1A and PRSS3, and exposure to both tobacco and arsenic in bladder cancer. 15987713 2006
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 Therapeutic disease CTD_human We, therefore, examined, in a population-based study of human bladder cancer, the relationship between epigenetic silencing of three tumor suppressor genes, p16(INK4A), RASSF1A and PRSS3, and exposure to both tobacco and arsenic in bladder cancer. 15987713 2006
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 GeneticVariation disease BEFREE Using methylation-specific PCR (MSP), we examined the methylation status of p16(INK4a) and p14(ARF) in 64 samples from 45 bladder cancer patients (34 males, 11 females). 16316628 2006
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 Biomarker disease BEFREE We, therefore, examined, in a population-based study of human bladder cancer (n = 351), the relationship between epigenetic silencing of the tumor-suppressor genes, p16(INK4A), RASSF1A, PRSS3, and the four SFRP genes and exposure to both tobacco and arsenic in bladder cancer. 17119258 2006
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 Biomarker disease BEFREE To determine p53 and p16 status as molecular markers of bladder cancer, in histologically proven benign bladder biopsies, obtained from lesions suspect for malignancy as judged by fluorescence cystoscopy. 17021825 2006
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 Biomarker disease CTD_human We, therefore, examined, in a population-based study of human bladder cancer, the relationship between epigenetic silencing of three tumor suppressor genes, p16(INK4A), RASSF1A and PRSS3, and exposure to both tobacco and arsenic in bladder cancer. 15987713 2006
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.600 Biomarker disease LHGDN Using methylation-specific PCR (MSP), we examined the methylation status of p16(INK4a) and p14(ARF) in 64 samples from 45 bladder cancer patients (34 males, 11 females). 16316628 2006